AMPA receptor

AMPA receptor
Name	AMPA receptor
Function	Ionotropic glutamate receptor

AMPA receptor AMPA receptor is an ionotropic glutamate receptor mediating fast excitatory neurotransmission in the central nervous system and across regions such as the cerebral cortex, hippocampus, and cerebellum. Discovered through studies that involved investigators affiliated with institutions like the National Institutes of Health and universities such as Harvard University and University of California, San Francisco, the receptor has been a focal point in research linking synaptic physiology to disorders investigated by organizations including the World Health Organization and funding bodies like the Wellcome Trust. Its study interfaces with work on synaptic plasticity by figures associated with Cold Spring Harbor Laboratory, Max Planck Society, and research reported in journals such as Nature and Science.

Structure and Subunit Composition

AMPA receptors are tetrameric assemblies formed by combinations of homologous subunits named GluA1, GluA2, GluA3, and GluA4 (also known as GluR1–4), characterized originally in laboratories at Stanford University and Massachusetts Institute of Technology. Each subunit contains an extracellular amino-terminal domain with homology to proteins studied at the European Molecular Biology Laboratory, a ligand-binding domain analogous to architectures solved by researchers at Protein Data Bank, and a transmembrane ion channel pore similar to descriptions from the National Science Foundation-funded structural programs. The presence or RNA editing status of the GluA2 subunit at the Q/R site, identified in work linked to Cold Spring Harbor Laboratory and Yale University, determines calcium permeability and rectification properties, a principle that shaped follow-up studies at institutes such as the Salk Institute and Johns Hopkins University.

Functional Properties and Synaptic Physiology

AMPA receptors mediate rapid depolarizing postsynaptic currents in circuits studied in the hippocampus, neocortex, amygdala, and spinal cord, with kinetics described in electrophysiological work from laboratories at University College London and Karolinska Institute. Their activation by glutamate released from presynaptic terminals in projections involving the entorhinal cortex and thalamus yields excitatory postsynaptic potentials measured in experiments associated with groups at Columbia University and University of Cambridge. Interactions with voltage-gated channels explored by teams at University of Oxford and synaptic integration models published in Proceedings of the National Academy of Sciences show how AMPA receptor-mediated conductances shape firing in circuits implicated in functions studied at the National Institute of Mental Health and Max Planck Institute for Brain Research.

Regulation and Trafficking

Trafficking of AMPA receptors to and from the synaptic membrane involves protein complexes and signaling cascades identified by researchers at Cold Spring Harbor Laboratory, National Institutes of Health, and ETH Zurich. Post-translational modifications such as phosphorylation by kinases like CaMKII and PKA, studied at institutions including University of California, Berkeley and Rockefeller University, modulate surface expression and channel conductance. Interactions with auxiliary proteins, including transmembrane AMPA receptor regulatory proteins characterized in collaborations involving Imperial College London and Duke University, and scaffolding partners such as PSD-95—originally described in research linked to Massachusetts General Hospital and Rutgers University—control synaptic localization, anchoring reminiscent of cytoskeletal associations delineated by groups at University of Pennsylvania.

Role in Development and Plasticity

During developmental windows described in developmental neurobiology programs at Stanford University and University of Cambridge, AMPA receptor composition and synaptic delivery guide processes such as synaptogenesis and circuit refinement in regions like the visual cortex and auditory cortex. Long-term potentiation and long-term depression phenomena, elucidated in seminal studies from laboratories affiliated with the Salk Institute and University of California, San Diego, depend on dynamic regulation of AMPA receptor number and subunit composition at postsynaptic densities. These mechanisms have been linked to behavioral and cognitive studies from centers such as Princeton University and MIT, influencing models of learning and memory also pursued at the Howard Hughes Medical Institute.

Pharmacology and Modulation

Pharmacological modulation of AMPA receptors includes agonists, antagonists, and positive allosteric modulators characterized in drug discovery programs at pharmaceutical companies like Pfizer and Novartis and academic collaborations with Yale University and Columbia University. Noncompetitive antagonists and selective blockers were developed in medicinal chemistry efforts associated with Bristol-Myers Squibb and tested in preclinical studies at Johns Hopkins University. Perampanel, an AMPA receptor antagonist approved for use by regulatory bodies such as the European Medicines Agency and Food and Drug Administration, exemplifies translation from receptor pharmacology to therapeutics examined in clinical research networks including ClinicalTrials.gov registries. Allosteric modulators researched at institutions like University of Oxford alter gating and desensitization kinetics, influencing outcomes measured in translational neurology studies at Mayo Clinic.

Pathophysiology and Clinical Relevance

Dysregulation of AMPA receptor signaling has been implicated in conditions studied at specialty centers such as the National Institute of Neurological Disorders and Stroke and university hospitals including Charité – Universitätsmedizin Berlin and Massachusetts General Hospital. Altered trafficking or subunit editing correlates with excitotoxicity observed in ischemic stroke models and neurodegenerative processes investigated by consortia like the Alzheimer's Disease Neuroimaging Initiative and researchers at University College London and UCL Queen Square Institute of Neurology. Epilepsy, mood disorders, and neurodevelopmental disorders examined in clinical programs at Johns Hopkins Hospital and Mount Sinai Hospital show links to AMPA receptor function, informing therapeutic strategies evaluated in trials supported by organizations including the Wellcome Trust and European Research Council. Ongoing translational efforts at centers such as the Translational Neuroscience Centre aim to harness knowledge of AMPA receptor biology for interventions in cognitive impairment and psychiatric illness.

Category:Neurotransmitter receptors